Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Mihailovich

Physician Assistant Raleigh, NC Physician Assistant

NPI 1427434745 CMS profile 10562964

3100 Duraleigh Rd Ste 200, Raleigh, NC 27612

Open in the dashboard

General payments

$7,935

448 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Mihailovich of Raleigh, NC is reported in the CMS Open Payments database as having received $7,935 across 448 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42 2
2024 General $1,272 69
2023 General $1,900 104
2022 General $1,802 107
2021 General $2,918 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Mihailovich
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nicole Mihailovich were reported at $42. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nicole Mihailovich Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,918 $132 $37–$438 $132
2022 $1,802 $155 $48–$522 $149
2023 $1,900 $167 $52–$557 $160
2024 $1,272 $178 $55–$600 $164
2025 $42 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,830 100 payments
  2. AbbVie, Inc. $1,245 85 payments
  3. Lilly USA, LLC $880 56 payments
  4. AstraZeneca Pharmaceuticals LP $752 30 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $622 37 payments
  6. Amgen Inc. $246 19 payments
  7. Esperion Therapeutics, Inc. $236 7 payments
  8. Astellas Pharma US Inc $230 10 payments
  9. Pfizer Inc. $212 13 payments
  10. Janssen Pharmaceuticals, Inc $190 13 payments
  11. Other $1,490 78 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,818 444 payments
  2. Education $117 4 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $999 59 payments
  2. Ozempic $997 59 payments
  3. Wegovy $555 22 payments
  4. UBRELVY $552 41 payments
  5. MOUNJARO $525 28 payments
  6. FARXIGA $430 17 payments
  7. JARDIANCE $416 25 payments
  8. VRAYLAR $410 21 payments
  9. STIOLTO RESPIMAT $337 22 payments
  10. QULIPTA $315 23 payments
  11. Other $4,749 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

2,494

Median for Physician Assistant: 241

Drug cost

$307,858

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 51 $75,639
Ozempic Semaglutide Brand 25 $37,125
Januvia Sitagliptin Phosphate Brand 16 $28,386
Eliquis Apixaban Brand 16 $25,694
Mounjaro Tirzepatide Brand 14 $22,799
Trulicity Dulaglutide Brand 14 $22,497
Rybelsus Semaglutide Brand 16 $20,243
Linzess Linaclotide Brand 14 $19,393
Tresiba Flextouch U-200 Insulin Degludec Brand 15 $9,646
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,689

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$10,348

Medicare's payments for the services billed

Medicare patients

87

Average age 70

Services billed

210

54 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 36%
Diabetes 31%
Ischemic heart disease 26%
Heart failure 22%
Chronic kidney disease 22%
Depression 22%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $120
$120 — —
VRAYLAR
  • AbbVie, Inc. $109
$109 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $89
$89 — —
RYBELSUS
  • Novo Nordisk Inc $88
$88 16 —
Ozempic
  • Novo Nordisk Inc $88
$88 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record